Detalles de la búsqueda
1.
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.
Eur J Nucl Med Mol Imaging
; 50(13): 3970-3981, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37563351
2.
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT.
Eur J Nucl Med Mol Imaging
; 48(1): 204-216, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32572559
3.
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.
Eur J Nucl Med Mol Imaging
; 47(10): 2322-2327, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140802
4.
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Eur J Nucl Med Mol Imaging
; 47(12): 2776-2786, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338306
5.
Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
Eur J Nucl Med Mol Imaging
; 46(3): 718-727, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30343432
6.
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
Eur J Nucl Med Mol Imaging
; 46(9): 1902-1910, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31187162
7.
PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment.
Eur J Nucl Med Mol Imaging
; 46(9): 1869-1877, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31190177
8.
The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia.
Intern Med J
; 49(8): 1001-1006, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30515932
9.
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Lancet Oncol
; 19(6): 825-833, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29752180
10.
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.
Eur J Nucl Med Mol Imaging
; 44(3): 476-489, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27678267
11.
Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.
Eur J Nucl Med Mol Imaging
; 42(1): 25-32, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25125202
12.
Response to COVID-19 vaccination imaged by PD-L1 PET scanning.
EJNMMI Rep
; 8(1): 16, 2024 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38844699
13.
SUVfdg: A standard-uptake-value (SUV) body habitus normalizer specific to fluorodeoxyglucose (FDG) in humans.
PLoS One
; 17(4): e0266704, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35446848
14.
Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei.
Eur J Surg Oncol
; 48(7): 1606-1613, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35148916
15.
Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.
J Nucl Med
; 63(2): 218-225, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34049983
16.
Prospective evaluation of 18F-FDG positron emission tomography in the preoperative staging of patients with hepatic colorectal metastases.
Hepatobiliary Surg Nutr
; 11(4): 539-554, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36016741
17.
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.
BMJ Open
; 12(11): e056708, 2022 11 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36400733
18.
Nodal metabolic tumour volume on baseline 18 F-FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curative-intent chemoradiotherapy/radiotherapy.
J Med Imaging Radiat Oncol
; 65(6): 748-754, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34318603
19.
Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.
J Gastrointest Surg
; 24(4): 899-906, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31090036
20.
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med
; 61(6): 857-865, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31732676